Politician trade (House)

Johnson & Johnson (JNJ): Rep. Josh Gottheimer (NJ05) disclosed a partial sale $1K–$15K

Rep. Josh Gottheimer (NJ05) disclosed a partial sale of Johnson & Johnson in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
18 days
Disclosure lag
Traded
Jun 21, 2024
Disclosed
Jul 9, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jul 14, 2023CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  2. Nov 10, 2023CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  3. Jun 4, 2024Congress · 2 peopleMembers of Congress: 2 purchases
  4. Jun 13, 2024CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
  5. Jun 21, 2024 · this disclosureCongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000

What came next

  1. Jul 1, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  2. Jul 2, 2024Congress · 1 personMembers of Congress: 2 purchases
  3. Jul 3, 2024Congress · 1 personMembers of Congress: 2 sales
  4. Jul 16, 2024CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
  5. Aug 2, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  6. Aug 5, 2024FDARecall: ImpellaCP SmartAssistSetAPAC, Delo1895; Product Code: 1000302;
  7. Aug 5, 2024FDARecall: Impella CP Pump 371 Set, Clinical Trial; Product Code: 0048-0040;
  8. Aug 6, 2024FDAFDA device clearance: Abiomed 14Fr Low Profile Introducer Kit
  9. Aug 7, 2024CongressDisclosed purchase of JNJ — reported range $15,001 - $50,000
  10. Aug 19, 2024FDAFDA drug approval: Rybrevant
  11. Aug 19, 2024FDAFDA drug approval: Lazcluze
  12. Sep 4, 2024CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  13. Sep 6, 2024FDAFDA device clearance: MENTOR™ MemoryGel™ Enhance Single Use Gel Sizer
  14. Sep 9, 2024FDAFDA device clearance: TriALTIS™ Spine System
  15. Sep 10, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  16. Sep 11, 2024FDAFDA drug approval: Tremfya
  17. Sep 11, 2024FDAFDA device clearance: HEALIX ADVANCE Knotless anchors; HEALIX ADVANCE Self-Punching anchors
  18. Sep 16, 2024FDAFDA device clearance: CROSSNAV Navigation Enabled Instruments and UNAS Navigation Arrays
  19. Sep 19, 2024FDAFDA drug approval: Rybrevant
  20. Sep 25, 2024FDARecall: Coated VICRYL Polyglactin 910 Suture VIO 36IN(90CM) USP0(M3.5) S/A CT, Product Number J358H
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Johnson & Johnson

For Johnson & Johnson, OQRO holds 14 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 119 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JNJ page.

Other recent filings by Rep. Josh Gottheimer (NJ05)

The full history of Rep. Josh Gottheimer (NJ05) is on the profile page.

How this filing works

Explore the data

Other disclosures at Johnson & Johnson

Everything OQRO holds on this company is on its JNJ page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data